ENLV (Enlivex) ROE % Adjusted to Book Value: 5,659.33% (As of Dec. 2025)


ENLV Enlivex Ltd ENLV
31 GF Score
Price $7.26
! 2 Warning Signs
View Full Analysis

What is Enlivex ROE % Adjusted to Book Value?

Enlivex ENLV -1.94% 31 ROE % Adjusted to Book Value is 5,659.33% as of Dec. 2025. GuruFocus rates ENLV with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Enlivex's ROE % for the quarter that ended in Dec. 2025 was 509.34%. Enlivex's PB Ratio for the quarter that ended in Dec. 2025 was 0.09. Enlivex's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 5,659.33%.

Enlivex ROE % Adjusted to Book Value Related Terms

Enlivex ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Enlivex's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enlivex ROE % Adjusted to Book Value Chart

Enlivex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.79 -34.20 -40.05 -47.82 1,401.89

Enlivex Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -70.54 -55.77 -26.90 -33.30 5,659.33

ENLV vs CNTB, SMNR, MENS: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Enlivex's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enlivex ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Enlivex's ROE % Adjusted to Book Value falls into.


ENLV
31GF Score
Enlivex Ltd ENLV
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enlivex ROE % Adjusted to Book Value Calculation

Enlivex's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=126.17% / 0.09
=1,401.89%

Enlivex's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=509.34% / 0.09
=5,659.33%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 5,659.33% mean?
Enlivex (ENLV) has a ROE % Adjusted to Book Value of 5,659.33% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Enlivex and its competitors.
Is Enlivex's ROE % Adjusted to Book Value too high?
Enlivex's current ROE % Adjusted to Book Value is 5,659.33%. Overall, Enlivex has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Enlivex's ROE % Adjusted to Book Value compare to CNTB and SMNR?
Enlivex's ROE % Adjusted to Book Value of 5,659.33% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Enlivex and its competitors. Enlivex's current ROE % Adjusted to Book Value is 5,659.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enlivex stock overvalued right now?
Enlivex (ENLV) has a current ROE % Adjusted to Book Value of 5,659.33%. The current ROE % Adjusted to Book Value is 5,659.33%. Enlivex's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Enlivex (ENLV), the current ROE % Adjusted to Book Value is 5,659.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enlivex Business Description

Other Exchanges 1BT:Germany
Address 14 Einstein Street, Weizmann Science Park, Ness Ziona, ISR, 7403618
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
31GF Score

Get the complete analysis for ENLV

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.26
Price